Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map

References

• Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER, Brightling CE, Burney P, Bush A, Busse WW, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126(5):926–938. doi:10.1016/j.jaci.2010.07.019.
   PubMed Web of Science ®Google Scholar
• GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barcala FJ, Aboal J, Carreira JM, Rodriguez-Alvarez MX, Puga A, Sanjose E, Pintos M, Valdes L. Trends of asthma mortality in Galicia from 1993 to 2007. J Asthma. 2012;49(10):1016–1020. doi:10.3109/02770903.2012.728272.
   PubMedGoogle Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Gonzalez Barcala FJ, La Fuente-Cid RD, Alvarez-Gil R, Tafalla M, Nuevo J, Caamaño-Isorna F. Factors associated with a higher prevalence of work disability among asthmatic patients. J Asthma. 2011;48(2):194–199. doi:10.3109/02770903.2010.539294.
   PubMed Web of Science ®Google Scholar
• González Barcala FJ, de la Fuente-Cid R, Alvarez-Gil R, Tafalla M, Nuevo J, Caamaño-Isorna F. Factors associated with asthma control in primary care patients: the CHAS study. Arch Bronconeumol. 2010;46(7):358–363. doi:10.1016/j.arbres.2010.01.007.
   PubMed Web of Science ®Google Scholar
• Reibman J, Tan L, Ambrose C, Chung Y, Desai P, Llanos J-P, Moynihan M, Tkacz J. Clinical and economic burden of severe asthma among US patients treated with biologic therapies. Ann Allergy Asthma Immunol. 2021;127(3):318–325.e2. doi:10.1016/j.anai.2021.03.015.
   PubMed Web of Science ®Google Scholar
• Quirce S, Plaza V, Picado C, Vennera M, Casafont J. Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in Spain. J Investig Allergol Clin Immunol. 2011;21(6):466–471.
   PubMed Web of Science ®Google Scholar
• Hekking P-PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015 Apr;135(4):896–902. doi:10.1016/j.jaci.2014.08.042.
   PubMed Web of Science ®Google Scholar
• Sweeney J, Patterson CC, Menzies-Gow A, Niven RM, Mansur AH, Bucknall C, Chaudhuri R, Price D, Brightling CE, Heaney LG, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71(4):339–346. doi:10.1136/thoraxjnl-2015-207630.
   PubMed Web of Science ®Google Scholar
• Casan Clarà P, Martínez González C. Accumulated dose of systemic corticosteroids: significant medical information. Arch Bronconeumol. 2020;56(12):777–778. doi:10.1016/j.arbres.2020.01.007.
   PubMed Web of Science ®Google Scholar
• Casan Clarà P, Martínez González C. Biologics in the treatment of asthma. Arch Bronconeumol (Engl Ed)). 2020;56(3):137–138. doi:10.1016/j.arbres.2019.03.024.
   PubMed Web of Science ®Google Scholar
• Doroudchi A, Pathria M, Modena BD. Asthma biologics: comparing trial designs, patient cohorts and study results. Ann Allergy Asthma Immunol. 2020;124(1):44–56. doi:10.1016/j.anai.2019.10.016.
   PubMed Web of Science ®Google Scholar
• Blanco-Aparicio M, Calvo-Alvarez U, González-Barcala FJ. Biologics in asthma: don’t let the magic bullets sink the boat. Arch Bronconeumol. 2021;57(6):383–384.
   PubMed Web of Science ®Google Scholar
• Krings JG, McGregor MC, Bacharier LB, Castro M. Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent. J Allergy Clin Immunol Pract. 2019;7(5):1379–1392.
   PubMed Web of Science ®Google Scholar
• Arismendi E, Picado Vallés C. Current role of biomarkers in severe uncontrolled asthma. Arch Bronconeumol (Engl Ed). 2020;56(6):347–348. doi:10.1016/j.arbres.2019.08.001.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Albers FC, Chipps B, Muñoz X, Devouassoux G, Bergna M, Galkin D, Azmi J, Mouneimne D, Price RG, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716–1726. doi:10.1111/all.13850.
   PubMed Web of Science ®Google Scholar
• Cisneros C, Díaz-Campos RM, Marina N, Melero C, Padilla A, Pascual S, Pinedo C, Trisán A. Accreditation of specialized asthma units for adults in Spain: an applicable experience for the management of difficult-to-control asthma. J Asthma Allergy. 2017;10:163–169. doi:10.2147/JAA.S131506.
   PubMed Web of Science ®Google Scholar
• Akenroye AT, Heyward J, Keet C, Caleb Alexander G. Lower use of biologics for the treatment of asthma in publicly insured individuals. J Allergy Clin Immunol Pract. 2021. doi:10.1016/j.jaip.2021.01.039.
   Web of Science ®Google Scholar
• Inselman JW, Jeffery MM, Maddux JT, Shah ND, Rank MA. Trends and disparities in asthma biologic use in the United States. J Allergy Clin Immunol Pract. 2020;8(2):549–554.e1. doi:10.1016/j.jaip.2019.08.024.
   PubMed Web of Science ®Google Scholar
• https://www.mscbs.gob.es/ciudadanos/prestaciones/centrosServiciosSNS/hospitales/. [accessed 2020 October 9].
   Google Scholar
• ine.es [accessed 2020 October 9].
   Google Scholar
• Jeffery MM, Shah ND, Karaca-Mandic P, Ross JS, Rank MA. Trends in omalizumab utilization for asthma: evidence of suboptimal patient selection. J Allergy Clin Immunol Pract. 2018;6(5):1568–1577.e4. doi:10.1016/j.jaip.2017.07.034.
   PubMed Web of Science ®Google Scholar
• https://www.gemasma.com/. [accessed 2020 December 10].
   Google Scholar
• https://ginasthma.org/gina-reports/. [accessed 2020 December 10].
   Google Scholar
• Kharat AA, Borrego ME, Raisch DW, Roberts MH, Blanchette CM, Petersen H. Assessing disparities in the receipt of inhaled corticosteroid prescriptions for asthma by Hispanic and non-Hispanic white patients. Ann Am Thorac Soc. 2015;12(2):174–183. doi:10.1513/AnnalsATS.201405-186OC.
   PubMed Web of Science ®Google Scholar
• Frøssing L, Silberbrandt A, Von Bülow A, Backer V, Porsbjerg C. The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma. J Allergy Clin Immunol Pract. 2021;9(3):1267–1275. doi:10.1016/j.jaip.2020.09.051.
   PubMed Web of Science ®Google Scholar
• Entrenas Costa LM, Casas-Maldonado F, Soto Campos JG, Padilla-Galo A, Levy A, Álvarez Gutiérrez FJ, Gómez-Bastero Fernández AP, Morales-García C, Gallego Domínguez R, Villegas Sánchez G, et al. Economic impact and clinical outcomes of omalizumab add-on therapy for patients with severe persistent asthma: a real-world study. Pharmacoecon Open. 2019;3(3):333–342. doi:10.1007/s41669-019-0117-4.
   PubMed Web of Science ®Google Scholar
• Corren J, Panettieri RA.Jr. How important is adherence to inhaled medications before starting a biologic therapy for asthma?J Allergy Clin Immunol Pract. 2018;6(5):1578–1579. doi:10.1016/j.jaip.2018.07.007.
   PubMed Web of Science ®Google Scholar
• Facal D, López-Lois B, Gonzalez-Barcala FJ. A current overview of the psychological aspects of asthma in adults. Arch Bronconeumol (Engl Ed). 2020;56(8):475–476. doi:10.1016/j.arbres.2019.10.012.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Bjermer L, Brightling C, Brusselle GG, Chanez P, Chung KF, Custovic A, Diamant Z, Diver S, Djukanovic R, et al. ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. Eur Respir J. 2019;54(3):1900900. doi:10.1183/13993003.00900-2019.
   PubMed Web of Science ®Google Scholar
• Blakey JD, Gayle A, Slater MG, Jones GH, Baldwin M. Observational cohort study to investigate the unmet need and time waiting for referral for specialist opinion in adult asthma in England (UNTWIST asthma). BMJ Open. 2019;9(11):e031740. doi:10.1136/bmjopen-2019-031740.
   PubMed Web of Science ®Google Scholar
• Chung LP, Hew M, Bardin P, McDonald VM, Upham JW. Managing patients with severe asthma in Australia: current challenges with the existing models of care. Intern Med J. 2018;48(12):1536–1541. doi:10.1111/imj.14103.
   PubMed Web of Science ®Google Scholar
• Bernal-Delgado E, Garcia-Armesto S, Oliva J, Sanchez Martinez FI, Repullo JR, Pena-Longobardo LM, Ridao-Lopez M, Hernandez-Quevedo C. Spain: health system review. Health Syst Transit. 2018;20(2):1–179.
   PubMedGoogle Scholar
• Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, Domingo C, Hanania NA, Humbert M, Gow AM, et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50(6):1701782. doi:10.1183/13993003.01782-2017.
   PubMed Web of Science ®Google Scholar
• Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200.e20. doi:10.1016/j.jaci.2018.08.031.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Severe adult asthmas: integrating clinical features, biology, and therapeutics to improve outcomes. Am J Respir Crit Care Med. 2021;203(7):809–821. doi:10.1164/rccm.202009-3631CI.
   PubMed Web of Science ®Google Scholar
• Urrutia I, Aguirre U, Sunyer J, Plana E, Muniozguren N, Martínez-Moratalla J, Payo F, Antonio Maldonado J, Maria Anto J. Changes in the prevalence of asthma in the Spanish cohort of the European Community Respiratory Health Survey (ECRHS-II). Arch Bronconeumol. 2007;43(8):425–430. doi:10.1016/S1579-2129(07)60098-6.
   PubMed Web of Science ®Google Scholar
• López-Silvarrey-Varela A, Pértega-Díaz S, Rueda-Esteban S, Sánchez-Lastres JM, San-José-González MA, Sampedro-Campos M, Pérez-Castro T, Garnelo-Suárez L, Bamonde-Rodríguez L, López-Silvarrey-Varela J, et al. Prevalence and geographic variations in asthma symptoms in children and adolescents in Galicia (Spain). Arch Bronconeumol. 2011;47(6):274–282. doi:10.1016/j.arbr.2011.01.004.
   PubMed Web of Science ®Google Scholar
• von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Roell G, Thiemann HH. Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care Med. 1994;149(2):358–364. doi:10.1164/ajrccm.149.2.8306030.
   PubMed Web of Science ®Google Scholar
• Zhang G, Khoo S-K, Laatikainen T, Pekkarinen P, Vartiainen E, von Hertzen L, Hayden CM, Goldblatt J, Mäkelä M, Haahtela T, et al. Opposite gene by environment interactions in Karelia for CD14 and CC16 single nucleotide polymorphisms and allergy. Allergy. 2009;64(9):1333–1341. doi:10.1111/j.1398-9995.2009.02006.x.
   PubMed Web of Science ®Google Scholar
• Jandhyala R. Influence of pharmaceutical company engagement activities on the decision to prescribe: a pilot survey of UK rare disease medicine prescribers. Pharmaceut Med. 2020;34(2):127–134. doi:10.1007/s40290-019-00323-x.
   PubMed Web of Science ®Google Scholar
• Datta A, Dave D. Effects of physician-directed pharmaceutical promotion on prescription behaviors: longitudinal evidence. Health Econ. 2017;26(4):450–468. doi:10.1002/hec.3323.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barcala F-J, Calvo-Alvarez U, Garcia-Sanz M-T, Bourdin A, Pose-Reino A, Carreira J-M, Moure-Gonzalez J-D, Garcia-Couceiro N, Valdes-Cuadrado L, Muñoz X, et al. Characteristics and prognosis of near-fatal asthma exacerbations. Am J Med Sci. 2015;350(2):98–102. doi:10.1097/MAJ.0000000000000518.
   PubMed Web of Science ®Google Scholar
• González-García JG, Chalela R, Carballo N, Ausín P. Mild asthma and life-threatening exacerbations: is it time to take action?Arch Bronconeumol. 2020;56(6):395–396. doi:10.1016/j.arbres.2019.11.028.
   PubMed Web of Science ®Google Scholar
• Muñoz X, Romero-Mesones C, Cruz MJ. β2-agonists in asthma: the strange case of Dr. Jekyll and Mr. Hyde. Arch Bronconeumol. 2020;56(4):204–205. doi:10.1016/j.arbr.2019.07.010.
   PubMed Web of Science ®Google Scholar
• Cisneros Serrano C, Melero Moreno C, Almonacid Sánchez C, Perpiñá Tordera M, Picado Valles C, Martínez Moragón E, Pérez de Llano L, Soto Campos JG, Urrutia Landa I, García Hernández G, et al. Guidelines for severe uncontrolled asthma. Arch Bronconeumol. 2015;51(5):235–246. doi:10.1016/j.arbr.2015.03.010.
   PubMed Web of Science ®Google Scholar
• Álvarez-Gutiérrez FJ, Blanco-Aparicio M, Plaza V, Cisneros C, García-Rivero JL, Padilla A, Pérez-de Llano L, Perpiñá M, Soto-Campos G. Documento de consenso de asma grave en adultos. Actualización 2020. Open Respir Arch. 2020;2(3):158–174. doi:10.1016/j.opresp.2020.03.005.
   Google Scholar
• González-Barcala FJ, García-Couceiro N, Facal D. Education in asthma. Arch Bronconeumol. 2016;52(11):543–544. doi:10.1016/j.arbres.2016.02.011.
   PubMed Web of Science ®Google Scholar
• Porsbjerg C, Ulrik C, Skjold T, Backer V, Laerum B, Lehman S, Janson C, Sandstrøm T, Bjermer L, Dahlen B, et al. Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults. Eur Clin Respir J. 2018;5(1):1440868. doi:10.1080/20018525.2018.1440868.
   PubMed Web of Science ®Google Scholar
• Gillett K, Lippiett K, Astles C, Longstaff J, Orlando R, Lin SX, Powell A, Roberts C, Chauhan AJ, Thomas M, et al. Managing complex respiratory patients in the community: an evaluation of a pilot integrated respiratory care service. BMJ Open Respir Res. 2016;3(1):e000145. doi:10.1136/bmjresp-2016-000145.
   PubMed Web of Science ®Google Scholar
• Andrade LF, Sermet C, Pichetti S. Entry time effects and follow-on drug competition. Eur J Health Econ. 2016;17(1):45–60. doi:10.1007/s10198-014-0654-9.
   PubMed Web of Science ®Google Scholar